These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35883508)

  • 1. Advances in MUC1-Mediated Breast Cancer Immunotherapy.
    Li Z; Yang D; Guo T; Lin M
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1: a target molecule for cancer therapy.
    Singh R; Bandyopadhyay D
    Cancer Biol Ther; 2007 Apr; 6(4):481-6. PubMed ID: 18027437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances of MUC1 as a target for breast cancer immunotherapy.
    Yang E; Hu XF; Xing PX
    Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 immunotherapy.
    Beatson RE; Taylor-Papadimitriou J; Burchell JM
    Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation.
    Cao Y; Blohm D; Ghadimi BM; Stosiek P; Xing PX; Karsten U
    J Histochem Cytochem; 1997 Nov; 45(11):1547-57. PubMed ID: 9358856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
    Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
    Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PankoMab: a potent new generation anti-tumour MUC1 antibody.
    Danielczyk A; Stahn R; Faulstich D; Löffler A; Märten A; Karsten U; Goletz S
    Cancer Immunol Immunother; 2006 Nov; 55(11):1337-47. PubMed ID: 16485130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of mucin antigens in human cancers and its relationship with malignancy potential.
    Yonezawa S; Sato E
    Pathol Int; 1997 Dec; 47(12):813-30. PubMed ID: 9503463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.
    Bäckström M; Link T; Olson FJ; Karlsson H; Graham R; Picco G; Burchell J; Taylor-Papadimitriou J; Noll T; Hansson GC
    Biochem J; 2003 Dec; 376(Pt 3):677-86. PubMed ID: 12950230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1 and cancer.
    Taylor-Papadimitriou J; Burchell J; Miles DW; Dalziel M
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):301-13. PubMed ID: 10571020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
    Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
    J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.
    Matsukita S; Nomoto M; Kitajima S; Tanaka S; Goto M; Irimura T; Kim YS; Sato E; Yonezawa S
    Histopathology; 2003 Jan; 42(1):26-36. PubMed ID: 12493022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms.
    Yonezawa S; Nakamura A; Horinouchi M; Sato E
    J Hepatobiliary Pancreat Surg; 2002; 9(3):328-41. PubMed ID: 12353144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1 in Cancer Immunotherapy - New Hope or Phantom Menace?
    Syrkina MS; Rubtsov MA
    Biochemistry (Mosc); 2019 Jul; 84(7):773-781. PubMed ID: 31509728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.
    Chen W; Zhang Z; Zhang S; Zhu P; Ko JK; Yung KK
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer immunotherapy: current status and future prospects.
    Apostolopoulos V; McKenzie IF; Pietersz GA
    Immunol Cell Biol; 1996 Oct; 74(5):457-64. PubMed ID: 8912009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC1: An emerging target in cancer treatment and diagnosis.
    Qing L; Li Q; Dong Z
    Bull Cancer; 2022 Nov; 109(11):1202-1216. PubMed ID: 36184332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.
    Pathangey LB; Lakshminarayanan V; Suman VJ; Pockaj BA; Mukherjee P; Gendler SJ
    Biomolecules; 2016 Jun; 6(3):. PubMed ID: 27367740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.